| 摘要 |
Disclosed herein are pharmaceutical combinations comprising at least one thrombin receptor antagonist and at least one cardiovascular agent. Examples of cardiovascular agents suitable for co-formulation or co- administration with the thrombin receptor antagonist include an endothelin antagonist selected from the group consisting of tezosentan, bosentan, and sitaxsentan.
|
